Biotech Investors Want Drugs That Are Closer to Market

A trend of stock price downturns has made biotech investors wipe their hands of long-shot, early-stage drug developers. Instead, they’ll be focusing their funds on getting in bed with firms boasting drugs that are closer to market. Industry insiders say that small and mid-cap biotechs are suffering greatly from latent valuation and a dearth of landmark deals...